EP Patent

EP3471725A1 — Composition and method for proton pump inhibitor suspension

Assigned to Azurity Pharmaceuticals Inc · Expires 2019-04-24 · 7y expired

What this patent protects

Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stabili…

USPTO Abstract

Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stability.

Drugs covered by this patent

Patent Metadata

Patent number
EP3471725A1
Jurisdiction
EP
Classification
—
Expires
2019-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Azurity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.